GH IN CHILDREN WITH SHORT STATURE DUE TO GROWTH HORMONE INSENSITIVITY (GHIS)R

因生长激素不敏感而导致身材矮小的儿童的 GH (GHIS)R

• 批准号: 7607718
• 负责人: STEVEN D CHERNAUSEK
• 金额: $ 1.34万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607718
• 关键词: Blood Chemical Analysis; Cardiac; Child; Computer Retrieval of Information on Scientific Projects Database; Daily; End Point; Enrollment; Failure; Fibrinogen; Funding; Grant; Growth; Growth Factor; Height; Human; Institution; Insulin-Like Growth Factor I; Kidney; Measures; Monitor; Rate; Recombinants; Research; Research Personnel; Resources; Safety; Serum; Somatotropin; Source; Spleen; Subcutaneous Injections; United States National Institutes of Health; neutralizing antibody; normal aging; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. GInsulin-like growth factor I (IGF-I) is produced in response to pituitary growth hormone (GH) and is a major regulator of growth. Some children have IGF-I deficiency because they cannot respond to their own GH. They have severe growth retardation unresponsive to conventional therapies. This study evaluates the safety and efficacy of recombinant human IGF-I (rhIGF-I) given to short children with growth hormone insensitivity. Children must have clinically documented GH insensitivity with serum IGF-I levels that are low for age, normal GH secretion and evidence for failure of GH action, or have developed GH-neutralizing antibodies during GH treatment. Once enrolled, children are treated with subcutaneous injection of rhIGF-I twice daily until they reach final height. The primary efficacy endpoint is growth rate. Subjects are evaluated a minimum of every 6 months. Safety measures include monitoring of blood chemistries, kidney and spleen growth, and cardiac function.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 类似类似的生长因子I（IGF-I）是根据垂体生长激素（GH）产生的，是生长的主要调节剂。 有些孩子缺乏IGF-I，因为他们无法对自己的GH做出反应。他们对常规疗法无反应症。这项研究评估了重组人IGF-I（RHIGF-I）的安全性和有效性，赋予了患有生长激素不敏感性的短儿童。 儿童必须具有临床记录的GH不敏感性，血清IGF-I水平低，年龄较低，GH分泌正常和GH作用失败的证据，或者在GH治疗过程中已经开发了GH-中和抗体。 入学后，每天两次对儿童进行皮下注入Rhigf-I治疗，直到达到最终身高。 主要功效终点是增长率。 每6个月至少评估受试者。 安全措施包括监测血液化学，肾脏和脾脏生长以及心脏功能。